AN 86-YEAR-OLD WOMAN with hypertension, osteoporosis, and mild cognitive impairment presents with episodes of palpitations and heart “fluttering.” These episodes occur 1 to 2 times per week, last for up to several hours, and are associated with mild shortness of breath and reduced activity tolerance. She is widowed and lives in a retirement facility, but she is independent in activities of daily living. She has fallen twice in the past year without significant injury.

See related editorial, page 41

Guidelines for managing atrial fibrillation recommend systemic anticoagulation for almost all patients age 65 and older, but in practice up to 50% of older patients do not receive maintenance anticoagulation therapy. The most common reason physicians cite for withholding anticoagulation in older patients with atrial fibrillation is a perception of a high risk of falling and associated bleeding, especially intracranial hemorrhage.

The decision-making process is complex and should be shared with the patient and the patient’s family and caregivers.

Physical examination is unremarkable. An electrocardiogram demonstrates sinus rhythm with left ventricular hypertrophy. A 30-day event monitor reveals several episodes of paroxysmal atrial fibrillation that correspond with her symptoms. A subsequent echocardiogram shows normal left ventricular systolic function, mild diastolic dysfunction, and no significant valvular abnormalities. Laboratory studies, including thyroid-stimulating hormone, are normal.

What is this patient’s risk of stroke? What is her risk of major bleeding from anticoagulation? How should fall risk be addressed in the decision-making process? What other factors should be considered?

The prevalence of atrial fibrillation increases with age, and nearly half of patients with atrial fibrillation in the United States are 75 or older. In addition, older age is an independent risk factor for stroke in patients with atrial fibrillation, and the proportion of strokes at-

Dr. Hagerty is supported by a National Institutes of Health, National Research Service Award (5-T32-HL07081-40) from the National Heart, Lung, and Blood Institute.

doi:10.3949/ccjm.84a.16016
ATRIAL FIBRILLATION IN THE ELDERLY

TABLE 1
Annual risk of stroke based on CHADS\textsubscript{2} or CHA\textsubscript{2}DS\textsubscript{2}-VASc score

<table>
<thead>
<tr>
<th>Score</th>
<th>CHADS\textsubscript{2}\textsuperscript{11}</th>
<th>CHA\textsubscript{2}DS\textsubscript{2}-VASc\textsuperscript{12}</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.9%</td>
<td>0.0%</td>
</tr>
<tr>
<td>1</td>
<td>2.8%</td>
<td>1.3%</td>
</tr>
<tr>
<td>2</td>
<td>4.0%</td>
<td>2.2%</td>
</tr>
<tr>
<td>3</td>
<td>5.9%</td>
<td>3.2%</td>
</tr>
<tr>
<td>4</td>
<td>8.5%</td>
<td>4.0%</td>
</tr>
<tr>
<td>5</td>
<td>12.5%</td>
<td>6.7%</td>
</tr>
<tr>
<td>6</td>
<td>18.2%</td>
<td>9.8%</td>
</tr>
<tr>
<td>7</td>
<td>—</td>
<td>9.6%</td>
</tr>
<tr>
<td>8</td>
<td>—</td>
<td>12.5%</td>
</tr>
<tr>
<td>9</td>
<td>—</td>
<td>15.2%</td>
</tr>
</tbody>
</table>

CHADS\textsubscript{2}: 1 point each for congestive heart failure, hypertension, age ≥ 75, diabetes mellitus; 2 points for prior stroke or transient ischemic attack.

CHA\textsubscript{2}DS\textsubscript{2}-VASc: 1 point each for congestive heart failure, hypertension, age 65–74, diabetes mellitus, vascular disease (coronary artery disease, peripheral arterial disease, aortic aneurysm), sex category female; 2 points for age ≥ 75 and for prior stroke or transient ischemic attack.

In the aspirin group (absolute yearly risk reduction 2%, 95% confidence interval 0.7–3.2, number needed to treat 50 for 1 year). Importantly, the benefit of warfarin was similar in men and women, and in patients ages 75 to 79, 80 to 84, and 85 and older.

More recently, the oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban have been shown to be at least as effective as warfarin with respect to both stroke prevention and major bleeding complications, and subgroup analyses have confirmed similar outcomes in older and younger patients.\textsuperscript{4,5}

But despite the proven value of anticoagulation for stroke prevention in older adults, only 40% to 60% of older patients who are suitable candidates for anticoagulation actually receive it.\textsuperscript{6} Moreover, the proportion of patients who are treated declines progressively with age. The most frequently cited reason for nontreatment is perception of a high risk of falls and associated concerns about bleeding, especially intracranial hemorrhage.\textsuperscript{7–10}

\section*{BALANCING STROKE RISK VS BLEEDING RISK}

Balancing the risk of stroke against the risk of bleeding related to falls is a commonly encountered conundrum in older patients with atrial fibrillation.

\subsection*{Stroke risk}

The CHADS\textsubscript{2} score was, until recently, the most widely used method for assessing stroke risk in patients with nonvalvular atrial fibrillation. CHADS\textsubscript{2} assigns 1 point each for congestive heart failure, hypertension, age ≥ 75, and diabetes, and 2 points for prior stroke or transient ischemic attack (range 0–6 points). Annual stroke risk based on the CHADS\textsubscript{2} score ranges from about 2% to about 18% (Table 1).\textsuperscript{11}

The CHA\textsubscript{2}DS\textsubscript{2}-VASc score,\textsuperscript{12} a modification of CHADS\textsubscript{2}, appears to assess the risk of stroke more accurately, especially at the lower end of the scale, and recent guidelines for managing atrial fibrillation recommend using the CHA\textsubscript{2}DS\textsubscript{2}-VASc algorithm.\textsuperscript{13} CHA\textsubscript{2}DS\textsubscript{2}-VASc is similar to CHADS\textsubscript{2}, except that it assigns 1 point for ages 65 to 74, 2 points for ages 75 and older, 1 point for vascular disease (coronary artery disease, peripheral arterial...
disease, aortic aneurysm), and 1 point for female sex (Table 1).\textsuperscript{11,12}

For both CHADS\textsubscript{2} and CHA\textsubscript{2}DS\textsubscript{2}-VASc, systemic anticoagulation is recommended for patients who have a score of 2 or higher. Our patient’s CHADS\textsubscript{2} score is 2, and her CHA\textsubscript{2}DS\textsubscript{2}-VASc score is 4, corresponding to an annual estimated stroke risk of 4% with both scores (Table 1). Note, however, that the CHA\textsubscript{2}DS\textsubscript{2}-VASc score provides more information at the lower end of the spectrum.

### Bleeding risk

Several scoring systems for assessing bleeding risk have also been developed (Table 2).\textsuperscript{14–16} Of these, the HAS-BLED score has come to be used more widely in recent years.

Perhaps not surprisingly, some of the same factors associated with risk of stroke also predict increased risk of bleeding (eg, older age, hypertension, prior stroke).\textsuperscript{14} Note, however, that history of falling or high risk of falling is only included in one of the bleeding risk models (HEMORR\textsubscript{2}HAGES).\textsuperscript{15}

These tools are somewhat limited by their lack of consideration of concomitant antiplatelet therapy (only included in HAS-BLED) or history of bleeding (only ATRIA\textsuperscript{16} considers major and minor bleeding, HEMORR\textsubscript{2}HAGES does not specify bleeding severity, and HAS-BLED only considers major bleeding). The models also fail to include medications such as antibiotics or antiarrhythmic agents, which are commonly used by older patients with atrial fibrillation and may increase bleeding risk. In addition, all bleeding risk scores were developed for warfarin, and their applicability to patients treated with the newer oral anticoagulants has not been established.

At the time of presentation, our patient has a HAS-BLED score of 2 (1 point each for age and hypertension), placing her at intermediate risk of bleeding.\textsuperscript{14}

**Fear the clot, not the bleed**

So how does one balance the risk of stroke vs the risk of bleeding? An adage from the early days of thrombolytic therapy for acute myocardial infarction was “fear the clot, not the bleed.” In other words, in the present context the consequences of a thrombus embolizing from the heart to the brain are likely to be more devastating and more permanent than
the consequences of anticoagulation-associated hemorrhage.

Support for this view is underscored by a 2015 study by Lip et al., who examined stroke and bleeding risks and outcomes in a large real-world population of patients age 75 and older. The analysis included 819 patients ages 85 to 89 and 386 patients age 90 and older. The key finding was that the oldest patients derived the greatest net benefit from anticoagulation.

Moreover, the Canadian stroke registry of 3,197 patients, mean age 79, showed that advanced age was a more potent risk factor for ischemic stroke than it was for hemorrhagic stroke.

Thus, the benefit from anticoagulation in patients with atrial fibrillation does not appear to have an upper age limit.

Falls and Anticoagulation

Falls are an important source of morbidity, disability, and activity curtailment in older adults and, like atrial fibrillation, the incidence and prevalence of falls increase with age. In community-dwelling adults age 65 and older, the overall proportion with at least 1 fall in the preceding year ranges from about 30% to 40%. However, the rate increases with age and exceeds 50% in nursing home residents.

Although anticoagulation is associated with a higher risk of bleeding in patients who fall, the absolute risk is small.

In a study of older adults with nonvalvular atrial fibrillation, a history of falls or documented high risk of falling was associated with a risk of intracranial hemorrhage during follow-up that was 1.9 times higher. Importantly, however, this risk did not differ among patients treated with warfarin, aspirin, or no antithrombotic therapy. In this analysis, patients with a CHADS2 score of 2 or higher benefited from anticoagulation, whether or not they were considered to be at risk for falls.

In another study, it was estimated that an individual would have to fall 295 times in 1 year for the risk of fall-related major bleeding to outweigh the benefit of warfarin in reducing the risk of stroke.

Thus, based on available evidence, perception of a high risk of falling should not be construed as justification for withholding anticoagulation in older patients who are otherwise suitable candidates for such therapy.

At What Point Does Bleeding Risk Outweigh Anticoagulation Benefit?

Absolute contraindications to anticoagulation include an intracranial hemorrhage or neurosurgical procedure with high risk for bleeding within the past 30 days, an intracranial neoplasm or vascular abnormality with high risk of bleeding, recurrent life-threatening gastrointestinal or other bleeding events, and severe bleeding disorders, including severe thrombocytopenia.

In patients with atrial fibrillation at high risk of bleeding as assessed by one of the bleeding risk scores and relatively low risk of ischemic stroke, the risk of anticoagulation may outweigh the benefit, although no studies have specifically addressed this issue.

In patients with frequent falls, including injurious falls, the benefits of anticoagulation usually outweigh the risks of bleeding, but management should incorporate interventions designed to mitigate fall risk.

Finally, in patients with a poor prognosis approaching the end of life, the risks and burdens of anticoagulation may exceed the perceived benefits, in which case discontinuation of anticoagulation may be appropriate.

Should Our Patient Receive Anticoagulation?

As noted above, our patient has a high risk of stroke and a moderate risk of bleeding, and multiple lines of evidence indicate that the benefits of anticoagulation (ie, prevention of stroke and systemic embolization) substantially outweigh the risks of bleeding. Although she has a history of falls, which may seem to muddy the waters, this factor should not play a major role in decision-making. Moreover, her advanced age should, if anything, be considered a point in favor of anticoagulation.

A shared decision

But that is not the end of the story. Since there is tension between benefits and risks with ei-
ther approach (ie, anticoagulation or no anticoagulation), it is important to discuss the issues and options with the patient and relevant caregivers. Most older adults have witnessed the ravages of stroke in a friend or relative, and a recent study showed that most would be willing to accept a modest risk of bleeding to prevent a stroke.23

However, this is ultimately a personal decision for each patient, and in accordance with the principle of patient autonomy, the patient’s expressed wishes should be honored by using a process of shared decision-making.

**Which anticoagulant?**
Finally, what about the choice of anticoagulation? The complexities of using warfarin, including its narrow therapeutic range and myriad interactions with other medications and foods, can make it a less appealing option for both patient and provider.

We recommend a novel oral anticoagulant as first-line therapy in the absence of contraindications such as severe renal insufficiency, and prefer apixaban because it is the only agent shown to be superior to warfarin with respect to both stroke prevention and bleeding risk.24

Important disadvantages of the novel oral anticoagulants include their higher cost and lack of an effective antidote in the event of clinically significant bleeding (with the exception of idarucizumab, which was recently approved for reversal of serious bleeding associated with dabigatran), issues that may be of particular concern to older adults. While there is no therapeutic range to monitor for occult anemia may be needed.

Thus, selection of an anticoagulant should also be individualized through shared decision-making.

**Is aspirin alone an alternative?**
And what if the patient chooses to forgo anticoagulation? In that case, aspirin 75 to 325 mg/day may seem reasonable, but there is scant evidence that aspirin is beneficial for stroke prevention in patients with atrial fibrillation in this age group, and aspirin, too, is associated with an increased risk of bleeding.25

As a result, current US and European guidelines recommend a very limited role for aspirin as a single agent in the management of atrial fibrillation.26 The joint 2014 guidelines of the American Heart Association, American College of Cardiology, and Heart Rhythm Society give aspirin a class IIB recommendation (ie, it “may” be considered), level of evidence C (ie, very limited) for use as an alternative to no antithrombotic therapy or systemic anticoagulation only in patients with a CHA2DS2-VASc score of 1, thereby excluding all patients age 75 and older.13

In most cases, aspirin as sole prophylaxis against stroke in atrial fibrillation should be avoided in the absence of another indication for its use, such as coexisting coronary artery disease or peripheral arterial disease.

**A COMPLEX DECISION**

In summary, the decisions surrounding anticoagulation of elderly patients with nonvalvular atrial fibrillation are complex. Accurate assessment of stroke risk is key, and although bleeding risk is also an essential consideration, it is important not to overemphasize bleeding and fall risks in the decision-making process.


